Usage of heparan sulfate, integrins, and FAK in HPV16 infection.

Usage of heparan sulfate, integrins, and FAK in HPV16 infection.
复制标题

DOI:
10.1016/j.virol.2010.04.007
复制
发表时间:
2010-07-20
期刊:
影响因子:
3.7
通讯作者:
Meneses PI
Meneses PI
中科院分区:
医学3区
文献类型:
--
作者:
Abban CY;Meneses PI

文献摘要

参考文献

被引文献

相似文献

人乳头瘤病毒16型(Human Papillomavirus Type 16,HPV16)是宫颈癌的主要病原体。关于在感染中起重要作用的早期结合和信号分子的研究仍然缺乏。本研究分析了硫酸乙酰肝素、整合素和信号分子FAK在HPV 16感染人成人角质形成细胞系(HaCaTs)中的作用。我们的数据表明,感染需要结合的病毒颗粒硫酸乙酰肝素,然后通过激活粘着斑激酶通过整合素。在FAK抑制剂TAE226的存在下,感染减少。观察到TAE 226抑制病毒进入早期内体(已知感染途径)。这些发现表明FAK可以作为抗病毒治疗的新靶点。
Human Papillomavirus Type 16 (HPV16) is the major causative agent of cervical cancer. Studies regarding the early binding and signaling molecules that play a significant role in infection are still lacking. The current study analyses the role of heparan sulfate, integrins, and the signaling molecule FAK in HPV16 infection of human adult keratinocytes cell line (HaCaTs). Our data demonstrate that infection requires the binding of viral particles to heparan sulfate followed by activation of focal adhesion kinase through an integrin. Infections were reduced in the presence of the FAK inhibitor, TAE226. TAE226 was observed to inhibit viral entry to the early endosome a known infectious route. These findings suggest that FAK can serve as a novel target for antiviral therapy.
DOI: 10.1016/s0042-6822(02)00143-5
发表时间: 2003-03-01
期刊: VIROLOGY
影响因子: 3.7
作者:
Day, PM;Lowy, DR;Schiller, JT
通讯作者: Schiller, JT
DOI: 10.1128/jvi.75.3.1565-1570.2001
发表时间: 2001-02-01
影响因子: 5.4
作者:
Giroglou, T;Florin, L;Sapp, M
通讯作者: Sapp, M
DOI: 10.1128/jvi.00576-09
发表时间: 2009-08-15
影响因子: 5.4
作者:
Laniosz, Valerie;Dabydeen, Sarah A.;Meneses, Patricio I.
通讯作者: Meneses, Patricio I.
DOI: 10.1016/j.virol.2006.05.002
发表时间: 2006-09-01
期刊: VIROLOGY
影响因子: 3.7
作者:
Fothergill, Thomas;McMillan, Nigel A. J.
通讯作者: McMillan, Nigel A. J.
调节HPV 31 L1和L2衣壳蛋白的表达的机制和伪卵形进入。
DOI: 10.1186/1743-422x-4-19
发表时间: 2007-02-26
期刊: VIROLOGY JOURNAL
影响因子: 4.8
作者:
Hindmarsh, Patrick L.;Laimins, Laimonis A.
通讯作者: Laimins, Laimonis A.